Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.57 |
| ▸ | FAP | Q12884 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6185229 | 1.00 | DPP4 (0.57) | DPP4FAPDPP8 | |
| SCHEMBL6184680 | 0.90 | DPP4 (0.57) | DPP4FAPDPP8 | |
| SCHEMBL6187870 | 0.85 | DPP4 (0.60) | DPP4 | |
| SCHEMBL6336878 | 0.85 | DPP4 (0.66) | DPP4FAPDPP8 | |
| SCHEMBL6185171 | 0.85 | DPP4 (0.79) | DPP4FAPDPP8 | |
| SCHEMBL6184843 | 0.84 | DPP4 (0.57) | DPP4 | |
| SCHEMBL6185173 | 0.83 | DPP4 (0.65) | DPP4FAPDPP8 | |
| SCHEMBL6182784 | 0.82 | DPP4 (0.56) | DPP4 | |
| SCHEMBL6187740 | 0.82 | DPP4 (0.54) | DPP4 | |
| SCHEMBL6185150 | 0.81 | DPP4 (0.61) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256166-A1 | Nitrogen-containing compounds | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1535906-A1 | NITROGEN-CONTAINING COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256166-A1 | Nitrogen-containing compounds | DPP4, DPP3, DPP8 | DPP4 1/4885FAP 271/4885DPP8 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.